Skip to main content
OpenTrials

Clinical trial condition

Neuroendocrine Tumors

Explore clinical trials studying Neuroendocrine Tumors. Study availability and eligibility vary by location and protocol.

2,775 public trials 502 recruiting studies
Refine in advanced search Browse all conditions

Neuroendocrine Tumors trial results

Completed

Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

NCT03591731

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Neuroendocrine, +8 more
Locations
  • Centre Hospitalier du Pays d'Aix Aix-en-Provence, France
  • CHU d'Amiens-Picardie Amiens, France
  • CHU d'Angers Angers, France
  • Auxerre - CH Auxerre, France
View Trial Details
Completed

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

NCT00381641

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +37 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Decatur Memorial Hospital Decatur, Illinois, United States
  • NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois, United States
  • Ingalls Memorial Hospital Harvey, Illinois, United States
View all 17 locations
View Trial Details
Completed

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

NCT02437136

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +19 more
Locations
  • Yale University New Haven, Connecticut, United States
  • Emory University Atlanta, Georgia, United States
  • University of Maryland, Marlene and Stewart Greenbaum Cancer Center Baltimore, Maryland, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States
View Trial Details
Completed

BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

NCT03944356

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
Locations
  • Elbe Kliniken Stade - Buxtehude GmbH Buxtehude, Lower Saxony, Germany
  • Universitätsklinikum Essen, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie Essen, North Rhine-Westphalia, Germany
  • Universitätsklinik Kiel, Klinik für Dermatologie, Venerologie und Allergologie Kiel, Schleswig-Holstein, Germany
  • Katholisches Klinikum Bochum Bochum, Germany
View all 36 locations
View Trial Details

Related conditions